MPO-ANCA patients were treated with CYC (15 mg/kg IV per biweekly dose) and in the case of the most severely ill patient requiring VV-ECMO because of prolonged DAH and profound respiratory failure, CYC was combined with RTX (1000 mg IV per dose, two weeks apart). This evidence concerns the gene MPO and respiratory failure.